Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cholesterol drug reviews

This article was originally published in The Tan Sheet

Executive Summary

FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees will discuss the OTC switch potential of Merck's Mevacor (lovastatin) on July 13 and Bristol-Myers Squibb's Pravachol (pravastatin) on July 14, the agency confirms (1"The Tan Sheet" April 17, p. 3). The proposed OTC indication of both drugs is to "treat individuals with total cholesterol levels of 200-240 mg/dL and low density lipoprotein levels over 130 mg/dL," FDA reports. However, for Mevacor, the indication would apply to "men over 40 and postmenopausal women who do not have established cardiovascular disease or diabetes." Pravachol's proposed indication - "for individuals who do not have established cardiovascular disease or diabetes" - is not age- or gender-specific. A July 12 NDAC session also is scheduled, although a topic has yet to be announced. As a precursor to the advisory committee meeting, FDA is holding a public forum June 28-29 on the suitability of marketing certain Rx drug classes OTC (2"The Tan Sheet" May 1, p. 3)

You may also be interested in...



Rx-To-OTC Switch Flips On With June Public Forum, July NDAC Meeting

The suitability of specific Rx drug classes - such as antihypertensive agents, osteoporosis treatments and oral contraceptives - for OTC use will be examined by FDA at a June 28-29 meeting in Gaithersburg, Md.

Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting

FDA may be moving toward softening its firm stance, announced in a 1997 guidance, against over-the-counter use of cholesterol-lowering drugs.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel